DAG181

DRUG3 trials

Sponsors

Sunshine Lake Pharma Co., Ltd., Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

Conditions

Chronic HCV InfectionChronic Hepatics C Virus (HCV) Genotype 1CirrhosisNon-CirrhoticTreatment naïve

Phase 2

Phase 2 Study of Yimitasvir Phosphate Capsules

CompletedNCT03458481

Sunshine Lake Pharma Co., Ltd.Chronic HCV Infection

Start: 2017-07-31End: 2018-09-26Updated: 2020-03-18

Phase 3

Phase 3 Study of Yimitasvir Phosphate Capsules

CompletedNCT03487107

Sunshine Lake Pharma Co., Ltd.Chronic HCV Infection

Start: 2018-04-17End: 2019-06-25Updated: 2020-03-18

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients

CompletedNCT04155515

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.Chronic Hepatics C Virus (HCV) Genotype 1, Cirrhosis, Non-Cirrhotic +1

Start: 2019-06-13End: 2020-08-11Updated: 2021-02-04